Should I buy or sell Sartorius Stedim Biotech stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sartorius Stedim Biotech in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SDMHF shares. View SDMHF analyst ratings or view top-rated stocks .

How have SDMHF shares performed in 2024?

Sartorius Stedim Biotech's stock was trading at $263.75 at the beginning of the year. Since then, SDMHF shares have decreased by 14.6% and is now trading at $225.35. View the best growth stocks for 2024 here .

Is Sartorius Stedim Biotech a good dividend stock?

Sartorius Stedim Biotech (OTCMKTS:SDMHF) pays an annual dividend of $1.20 per share and currently has a dividend yield of 0.84%. The dividend payout ratio is 27.84%. This payout ratio is at a healthy, sustainable level, below 75%.

How do I buy shares of Sartorius Stedim Biotech?

Shares of SDMHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:SDMHF

Sartorius Stedim Biotech (SDMHF) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free SDMHF Stock Alerts

$214.00

-11.35 (-5.04%)

(As of 03:47 PM ET)

Compare

Today's Range: $211.25
▼
$215.24
50-Day Range: $225.35
▼
$299.86
52-Week Range: $175.12
▼
$321.11

Volume: 281 shs
Average Volume: 363 shs
Market Capitalization: N/A

P/E Ratio: 49.65
Dividend Yield: 0.56%
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Short Interest

Get Sartorius Stedim Biotech alerts:

Sartorius Stedim Biotech MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.46
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.06 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Sartorius Stedim Biotech.

0.0

Short Interest

Percentage of Shares Shorted
Short Interest Ratio / Days to Cover
Sartorius Stedim Biotech has a short interest ratio ("days to cover") of 193, which indicates bearish sentiment.
Change versus previous month
Short interest in Sartorius Stedim Biotech has recently increased by 7.22%, indicating that investor sentiment is decreasing significantly.

0.8

Dividend Strength

Dividend Yield
Sartorius Stedim Biotech has a dividend yield of 0.84%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Sartorius Stedim Biotech does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Sartorius Stedim Biotech is 27.84%. This payout ratio is at a healthy, sustainable level, below 75%.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SDMHF.

1.9

News and Social Media Coverage

News Sentiment
Sartorius Stedim Biotech has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Sartorius Stedim Biotech this week, compared to 0 articles on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sartorius Stedim Biotech insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 9.21% of the stock of Sartorius Stedim Biotech is held by institutions.

1.3

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Sartorius Stedim Biotech is 52.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.45.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sartorius Stedim Biotech is 52.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 215.55.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Sartorius Stedim Biotech Stock (OTCMKTS:SDMHF)

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.

SDMHF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SDMHF Stock News Headlines

April 17, 2024 | markets.businessinsider.com

Sartorius Stedim Biotech is about to announce its earnings — here's what Wall Street expects

April 16, 2024 | americanbankingnews.com

Sartorius Stedim Biotech (OTCMKTS:SDMHF) Shares Down 1.8%

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 28, 2024 | morningstar.com

Sartorius Stedim Biotech SA ADR SRTOY

February 20, 2024 | finance.yahoo.com

Sartorius Stedim Biotech S.A. (SDMHF)

February 7, 2024 | marketwatch.com

Sartorius Stedim Biotech Shares Fall After Capital Increase

February 7, 2024 | marketwatch.com

Sartorius Stedim Biotech Completes $1.3 Bln Capital Increase

January 26, 2024 | markets.businessinsider.com

Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2023 and provides 2024 guidance as well as new midterm outlook

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

October 19, 2023 | finance.yahoo.com

SARTORIUS (SARTF) Q3 Earnings Lag Estimates

July 21, 2023 | markets.businessinsider.com

Sartorius Stedim Biotech SA: Half-year results 2023 of Sartorius Stedim Biotech

July 21, 2023 | markets.businessinsider.com

Sartorius Stedim Biotech H1 Profit, Orders Down; Backs Weak FY23 Outlook

April 20, 2023 | markets.businessinsider.com

Sartorius Stedim Biotech Q1 Profit Declines, Sales Revenue Down 18.4% Organically; Confirms Outlook

January 26, 2023 | markets.businessinsider.com

Sartorius Stedim Biotech FY22 Profit Rises, Orders Down; Sees Growth In FY23; Raises FY25 Sales View

January 26, 2023 | technews.tmcnet.com

Preliminary results 2022 of Sartorius Stedim Biotech

October 19, 2022 | finance.yahoo.com

Nine-month results 2022 of Sartorius Stedim Biotech

July 21, 2022 | markets.businessinsider.com

Sartorius Stedim Biotech H1 Profit Climbs; Confirms FY22 Outlook - Quick Facts

April 21, 2022 | investing.com

Sartorius Stedim Earnings Miss, Revenue Beats In Q1

April 21, 2022 | seekingalpha.com

Sartorius Stedim Biotech S.A. Non-GAAP EPS of €2.21, revenue of €862.5M

February 8, 2022 | seekingalpha.com

Sartorius Stedim acquires Novasep's chromatography division; boosts sales guidance

January 28, 2022 | seekingalpha.com

Sartorius Stedim Biotech Non-GAAP EPS of €7.46, revenue of €2.89B

November 17, 2021 | benzinga.com

Single-use Bioreactors Market worth $8.8 billion by 2026 – Major Players are Sartorius Stedim Biotech (France), Thermo Fisher Scientific (US)

November 16, 2021 | finance.yahoo.com

Looking for a Growth Stock? 3 Reasons Why SARTORIUS (SARTF) is a Solid Choice

August 23, 2021 | finance.yahoo.com

McMaster, Sartorius Stedim Biotech team up to advance biomanufacturing processes with next-gen tech

See More Headlines

Receive SDMHF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sartorius Stedim Biotech and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Medical Instruments & Supplies
Sub-Industry: N/A
Current Symbol: OTCMKTS:SDMHF
CUSIP: N/A
CIK: N/A
Web: www.sartorius.com
Phone: (344) 284-5600
Fax: N/A
Employees: 10,662
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 52.29
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Rene Faber (Age 49)
CEO & DIrector
Comp: $584.92k
Mr. Rainer Lehmann (Age 49)
CFO & Member of Executive Board
Ms. Petra Muller
Head of Investor Relations
Ms. Petra Kirchhoff (Age 55)
Head of Corporate Communications & IR
Olivier Guitard
Head of Controlling BPS

Key Competitors

View All Competitors

SDMHF Stock Analysis - Frequently Asked Questions

Should I buy or sell Sartorius Stedim Biotech stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sartorius Stedim Biotech in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SDMHF shares.
View SDMHF analyst ratings or view top-rated stocks.
How have SDMHF shares performed in 2024?: Sartorius Stedim Biotech's stock was trading at $263.75 at the beginning of the year. Since then, SDMHF shares have decreased by 14.6% and is now trading at $225.35.
View the best growth stocks for 2024 here.
Is Sartorius Stedim Biotech a good dividend stock?: Sartorius Stedim Biotech (OTCMKTS:SDMHF) pays an annual dividend of $1.20 per share and currently has a dividend yield of 0.84%. The dividend payout ratio is 27.84%. This payout ratio is at a healthy, sustainable level, below 75%.
How do I buy shares of Sartorius Stedim Biotech?: Shares of SDMHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:SDMHF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Sartorius Stedim Biotech (SDMHF) Stock Price, News & Analysis